Eli Lilly (LLY) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the ...

Eli Lilly (NYSE: LLY) is the most valuable healthcare company in the world, worth more than $700 billion. Over the past 12 ...

Lately, however, Eli Lilly's stock has cooled. Shares have been essentially flat since July 2024. The market for GLP-1 ...

The investment will further support growth, while improving their margin in the future. Overall, I believe Eli Lilly is on a great trajectory to achieve profitable growth in the next several years.

Altria has an impressive streak of raising its dividend for 55 consecutive years. Eli Lilly's current streak only goes back ...

Eli Lilly (NYSE: LLY) and Veeva Systems (NYSE: VEEV). Here's what investors need to know about these market leaders that ...

Eli Lilly and Novo Nordisk occupy leading positions in the obesity and diabetes markets. Find out which is the better bargain ...

Eli Lilly (NYSE:LLY) has recently announced several developments, including positive Phase 2 results for their siRNA therapy ...

Eli Lilly (NYSE: LLY) has been around for almost ... in the years ahead has investors bullish on the company's future growth. However, there's also hope that Alzheimer's drug Kisunla, which ...

Eli Lilly (NYSE:LLY) experienced a 6% increase in price over the last quarter, coinciding with several major developments.

Due to this growth story ... The market tends to look to the future, so these estimates likely include continued momentum from Eli Lilly's GLP-1 agonists, including presumed FDA clearance for ...